Passive Alzheimer’s immunotherapy: A promising or uncertain option?
Ageing Research Reviews · 2023
DOI: 10.1016/j.arr.2023.101996 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Ageing Research Reviews, 2023. Verfasst von Poul F Høilund-Carlsen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern Denmark, Odense,…. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 69 Literaturangaben.
Themen: Demenz
Abstract (Originalsprache)
The US Food and Drug Administration (FDA)'s recent accelerated approval of two anti-amyloid antibodies for treatment of Alzheimer's disease (AD), aducanumab and lecanemab, has caused substantial debate. To inform this debate, we reviewed the literature on randomized clinical trials conducted with eight such antibodies focusing on clinical efficacy, cerebral amyloid removal, amyloid-related imaging abnormalities (ARIAs) and cerebral volumes to the extent such measurements have been reported. Two antibodies, donanemab and lecanemab, have demonstrated clinical efficacy, but these results remain uncertain. We further argue that the decreased amyloid PET signal in these trials is unlikely to be a one-to-one reflection of amyloid removal, but rather a reflection of increased therapy-related brain damage, as supported by the increased incidence of ARIAs and reported loss of brain volume. Due to these uncertainties of benefit and risk, we recommend that the FDA pauses existing approvals and approval of new antibodies until results of phase 4 studies with these drugs are available to inform on these risk-benefit uncertainties. We recommend that the FDA prioritize FDG PET and detection of ARIAs and accelerated brain volume loss with MRI in all trial patients, and neuropathological examination of all patients who die in these phase 4 trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark. Electronic address: pfhc@rsyd.dk.
- The Intervention Centre, Division of Technology and Innovation, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
- GCS-fMRI, Koelliker Hospital and Department of Psychology, University of Turin, Turin, Italy; FOCUS Lab, Department of Psychology, University of Turin, Turin, Italy.
- Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
- Section of Biophysical and Biomedicinal Chemistry, DTU Chemistry, Technical University of Denmark, Kongens, Lyngby, Denmark.
- Department of Neurosciences, Imaging and Clinical Sciences, "G. d'Annunzio" University of Chieti-Pescara, Chieti, Italy; CAST-Center for Advanced Studies and Technology, "G. d'Annunzio" University of Chieti-Pescara, Chi…
Zitieren
APA
Høilund-Carlsen, P. F., Revheim, M. E., Costa, T., Alavi, A., Kepp, K. P., Sensi, S. L., Perry, G., Robakis, N. K., Barrio, J. R., & Vissel, B. (2023). Passive Alzheimer’s immunotherapy: A promising or uncertain option?. Ageing Research Reviews. https://doi.org/10.1016/j.arr.2023.101996
Vancouver
Høilund-Carlsen PF, Revheim ME, Costa T, Alavi A, Kepp KP, Sensi SL, et al. Passive Alzheimer’s immunotherapy: A promising or uncertain option?. Ageing Research Reviews. 2023. doi:10.1016/j.arr.2023.101996
BibTeX
@article{HilundCarlsen2023,
author = {Høilund-Carlsen, Poul F and Revheim, Mona-Elisabeth and Costa, Tommaso and Alavi, Abass and Kepp, Kasper P and Sensi, Stefano L and Perry, George and Robakis, Nikolaos K and Barrio, Jorge R and Vissel, Bryce},
title = {Passive Alzheimer’s immunotherapy: A promising or uncertain option?},
journal = {Ageing Research Reviews},
year = {2023},
doi = {10.1016/j.arr.2023.101996}
}
EUVIMED